株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

MediGene AG : 製品パイプライン分析

MediGene AG - Product Pipeline Review - 2016

発行 Global Markets Direct 商品コード 224623
出版日 ページ情報 英文 42 Pages
即納可能
価格
本日の銀行送金レート: 1USD=114.71円で換算しております。
Back to Top
MediGene AG : 製品パイプライン分析 MediGene AG - Product Pipeline Review - 2016
出版日: 2016年09月30日 ページ情報: 英文 42 Pages
概要

MediGene AGは、癌や自己免疫疾患治療用の新薬の臨床研究、開発、販売を行っているバイオテクノロジー企業です。

当レポートでは、MediGene AGにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

MediGene AGの基本情報

MediGene AGの概要

  • 主要情報
  • 企業情報

MediGene AG:R&Dの概要

  • 主な治療範囲

MediGene AG:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

MediGene AG:パイプライン製品の概況

  • 最終段階にあるパイプライン製品
    • 登録前の製品/併用療法モダリティ
  • 治験段階にあるパイプライン製品
    • 第?相にある製品/併用療法モダリティ
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階にある製品/併用療法モダリティ
    • 創薬中の製品/併用療法モダリティ

MediGene AG:薬剤プロファイル

  • sinecatechins
  • 前立腺癌の細胞療法
  • RhuDex
  • 急性骨髄性白血病(AML)の細胞療法2
  • 急性骨髄性白血病(AML)の細胞療法
  • G-207
  • 腫瘍の FMNL1 標的細胞療法
  • ヒト・パピローマウイルス 血清型 16, 31用 ウイルス様粒子ワクチン
  • 白血病および自己免疫疾患治療のための抗TCRモノクローナル抗体

MediGene AG:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

MediGene AG:最近のパイプライン動向

MediGene AG:休止中のプロジェクト

MediGene AG:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • L1 モノクローナル抗体

MediGene AG:企業発表

MediGene AG:本社と子会社の所在地

付録

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC08145CDB

Summary

Global Markets Direct's, 'MediGene AG - Product Pipeline Review - 2016', provides an overview of the MediGene AG's pharmaceutical research and development focus.

The report provides comprehensive information on the therapeutics under development by MediGene AG, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the pipeline therapeutic landscape of MediGene AG
  • The report provides overview of MediGene AG including its business description, key facts, and locations and subsidiaries
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report assesses MediGene AG's pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report features MediGene AG's out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects

Reasons to buy

  • Evaluate MediGene AG's strategic position with total access to detailed information on its product pipeline
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for MediGene AG
  • Identify potential new clients or partners in the target demographic
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding MediGene AG's pipeline depth and focus of pipeline therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • MediGene AG Snapshot
    • MediGene AG Overview
    • Key Facts
  • MediGene AG - Research and Development Overview
    • Key Therapeutic Areas
  • MediGene AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • MediGene AG - Pipeline Products Glance
    • MediGene AG - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • MediGene AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • MediGene AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
    • MediGene AG - Unknown Stage Pipeline Products
      • Unknown Products/Combination Treatment Modalities
  • MediGene AG - Drug Profiles
    • Cellular Immunotherapy 1 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy 2 for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Acute Myeloblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy for Oncology - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target hTERT and Survivin for Prostate Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target MAGE-A1 for Multiple Myeloma - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Cellular Immunotherapy to Target Opa-Interacting Protein 4 and Wilm's Tumor 1 for Acute Myeloblastic Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 16, 31] (virus like particle) vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Monoclonal Antibodies to Target TCR for Autoimmune Disease and T-Cell Leukemia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • RhuDex - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • sinecatechins - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • MediGene AG - Pipeline Analysis
    • MediGene AG - Pipeline Products by Target
    • MediGene AG - Pipeline Products by Route of Administration
    • MediGene AG - Pipeline Products by Molecule Type
    • MediGene AG - Pipeline Products by Mechanism of Action
  • MediGene AG - Dormant Projects
  • MediGene AG - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • etomoxir
  • Monoclonal Antibody for Ovarian Cancer
  • MediGene AG - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • MediGene AG, Key Facts
  • MediGene AG - Pipeline by Indication, 2016
  • MediGene AG - Pipeline by Stage of Development, 2016
  • MediGene AG - Monotherapy Products in Pipeline, 2016
  • MediGene AG - Out-Licensed Products in Pipeline, 2016
  • MediGene AG - Out-Licensed Products/ Combination Treatment Modalities, 2016
  • MediGene AG - Phase III, 2016
  • MediGene AG - Phase II, 2016
  • MediGene AG - Phase I, 2016
  • MediGene AG - Preclinical, 2016
  • MediGene AG - Discovery, 2016
  • MediGene AG - Unknown, 2016
  • MediGene AG - Pipeline by Target, 2016
  • MediGene AG - Pipeline by Route of Administration, 2016
  • MediGene AG - Pipeline by Molecule Type, 2016
  • MediGene AG - Pipeline Products by Mechanism of Action, 2016
  • MediGene AG - Dormant Developmental Projects,2016
  • MediGene AG - Discontinued Pipeline Products, 2016
  • MediGene AG, Subsidiaries

List of Figures

  • MediGene AG - Pipeline by Top 10 Indication, 2016
  • MediGene AG - Pipeline by Stage of Development, 2016
  • MediGene AG - Monotherapy Products in Pipeline, 2016
  • MediGene AG - Out-Licensed Products in Pipeline, 2016
  • MediGene AG - Pipeline by Target, 2016
  • MediGene AG - Pipeline by Route of Administration, 2016
  • MediGene AG - Pipeline by Molecule Type, 2016
  • MediGene AG - Pipeline Products by Mechanism of Action, 2016
Back to Top